歌礼制药(01672.HK)急涨13%越百天线 治疗脂肪肝炎药物临床数据疗效显着
歌礼制药-B(01672.HK)治疗脂肪肝炎候选药物临床数据疗效显着,该股承昨天重越10天线势,今天进一步突破百天线(3.26元),最高见3.55元,现造3.5元,续涨13%,成交急增至1,848万股,涉资6,284万元。
歌礼公布,公司业务夥伴之一Sagimet公布有关口服(每日一次)非酒精性脂肪肝炎(NASH)候选药物TVB-2640二期(FASCINATE-1)临床试验数据。初步数据显示TVB-2640显着降低了肝脏脂肪含量(此试验的主要疗效终点),50mg组别中应答率为61%。另外,受试者还表现出肝功能和纤维化指标的改善。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.